Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01217437 · ClinicalTrials.gov registry record · Phase 2
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
NCT01217437: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01217437 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 108 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01217437, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well giving temozolomide and irinotecan hydrochloride together with or without bevacizumab works in treating young patients with recurrent or refractory medulloblastoma or central nervous system (CNS) primitive neuroectodermal tumors. Drugs used in chemotherapy, such as temozolomide and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether temozolomide and irinotecan hydrochloride are more effective with or without bevacizumab in treating medulloblastoma or CNS primitive neuroectodermal tumors.
Interventions
- DRUG Temozolomide
- BIOLOGICAL Bevacizumab
- DRUG Irinotecan Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2010-11-22 |
| Est. Completion | 2021-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01217437
The ClinicalTrials.gov registry entry for NCT01217437 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT01217437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01217437 about?
NCT01217437 is a clinical study titled "Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors". This randomized phase II trial studies how well giving temozolomide and irinotecan hydrochloride together with or without bevacizumab works in treating young patients with recurrent or refractory medulloblastoma or central nervous system (CNS) primitive neuroectodermal tumors. Drugs used in chemothe...
What is the current status of trial NCT01217437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2010-11-22. Estimated completion is 2021-06-30.
What interventions are being tested in trial NCT01217437?
The interventions under investigation include: Temozolomide (DRUG), Bevacizumab (BIOLOGICAL), Irinotecan Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01217437?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.